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ABSTRACT
A simple, rapid, precise and highly selective  Spectrophotometricmethod
was  developed  for  simultaneous  estima  tion  of  Montelukast  sodium  and
Acebrophylline in tablet dosage form. This method, involves the measurement of
absorbances  of  Montelukast  sodium  and  Acebrophylline  at  the  wavelengths
of250nm and 273nm.Ethanol was used as solvent. Linearity was observed in the
concentration  range  of  6-24µg/ml  for  Acebrophylline  and  4-24µg/ml  for
Montelukast  sodium.The accuracy of  the  method  was confirmed by recovery
studies  of  tablet  dosage  forms  and  was  found  to  be  98.33%  and  98.5%for
Acebrophylline  and  Montelukast  sodium  respectively.   Thus  the  proposed
method  was  found  to  be  rapid,  specific,  precise,  accurate  and  cost  effective
quality  control  tool  for  the  routine  analysis  of  Montelukast  sodium  and
Acebrophylline in bulk and combined dosage form. A selective, precise, isocratic
and  accurate  stability  indicating  reverse  phase  high  performance  liquid
chromatographic method was developed for the simultaneous determination of
Montelukast  sodium  and  Acebrophylline  in  the  tablet  dosage  form.  A
chromatographic separation was achieved on reverse phase BDS Hypersil C18
column (250 ×4.6 mm, 5µ). The mobile phase consists of mixture of 10 mM
phosphate  buffer  and  Acetonitrile.  The  pH  adjusted  to  4  using  1%
Orthophosphoric  acid.  The  flow  rate  was  1ml/min  and  the  effluents  were
monitored  at  the  detection  wavelength  of  250nm.  The  retention  times  of
Montelukast  sodium  and  Acebrophylline  were  found  to  be  6.7  and  3.6  min
respectively.  The  method  was  validated  for  the  linearity,  accuracy,  precision,
robustness, system suitability as per ICH guidelines.  Montelukast sodium and
Acebrophylline were found to be linear in the range of 100-1000 ng/ml with the
recoveries of 99.8% and 102.0%. 
Sample preparation
preparation
Sample analysis
analysis
Data handling 
handling
Sampletransport
and storage Archiving
Report generation
Information to customerSample collection and sampling
sampling
sampling
1. INTRODUCTION
Pharmaceutical analysis is a branch of practical chemistry that involves a series
of  process  for identification,  determination,  quantification  and  purification  of  a
substance,  separation  of  the  components  of  a  solution or  mixture,  or  determination
of structure of chemical  compounds.  The substance may be a single compound or a
mixture of compounds and it may be in any of the dosage form. The substance used as
pharmaceuticals are animals, plants, micro organisms, minerals and various synthetic
products.
 Analytical chemistry is the science that seeks ever improved means of measuring the
chemical composition of natural and artificial materials. 
The major stages of an analytical process are described as follows:
:
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Steps in analytical cycle
To be effective and efficient, analyzing samples requires expertise in: 
1. The chemistry that can occur in a sample
2. The total amount of sample available
3. Concentration range of analyte
4. Analysis and sample handling methods for a wide variety of problems (the tools-
of-the-trade)
5. Accuracy and precision of the method
6. Proper data analysis and record keeping
             Analytical chemistry is the science of obtaining, processing and communicating
information about the composition and structure of matter. In other words, it is the art
and science of determining what matter is and how much it exists. Analytical chemistry
also is concerned with developing the tools used to examine chemical compositions. It
is  concerned  with  the  chemical  characterization  of  matter  both  qualitatively  and
quantitatively.Qualitative analysis gives an indication of the identity of the chemical
species in the sample and quantitative analysis determines the amount of one or more of
these components.
Analytical methods can be separated into classical and instrumental. Classical methods
use  separation  techniques  such  as  precipitation,  extraction, and distillation and
qualitative  analysis  by  color,  odor,  or  melting  point.  The  quantitative  analysis  is
achieved by measurement of weight or volume. Instrumental methods use an apparatus
to  measure  physical  qualities  of  the  analyte  such  as lightabsorption, fluorescence,
or conductivity.  The  separation  of  materials  is  accomplished  by
using chromatography or electrophoresis methods.
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Common Techniques for analysis:
For analysis it is useful to consider chemical and physical characteristics that are useful
for qualitative or quantitative analysis and thus analysis can be divided into:-
Qualitative  analysis: It  is  performed  to  establish  composition  of  natural/synthetic
substances. These tests are performed to indicate whether the substance or compound is
present  in  the sample or not.  Various  qualitative tests  are  detection of  evolved gas,
formation of precipitates, limit tests, colour change reactions, melting point and boiling
point test etc.
Quantitative analysis: These techniques are mainly used to quantify any compound or
substance in the sample. These techniques are based in (a) the quantitative performance
of  suitable chemical  reaction and  either  measuring  the  amount  of  reagent  added  to
complete the reaction or measuring the amount of reaction product obtained, (b) the
characteristic  movement of  a  substance through a defined medium under controlled
conditions,  (c)  electrical  measurement,  (d)  measurement  of  some  spectroscopic
properties of the compound.
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The various physical properties employed for analysis with their instrumental methods
are given in the table below.
S.n
o
Physical property
measured
Instrumental method based on the
measurement of property
1 Absorption of Radiation
Spectrophotometry (X-ray, UV, Visible, IR):
Colorimetry, Atomic absorption, NMR.
2 Emission of Radiation
Emission spectroscopy(X-ray, UV, Visible, IR):
Flame photometry, Fluorescence (X-ray, UV,
Visible)
3 Scattering of Radiation Turbidimetry, Nephelometry
4 Refraction of Radiation Refractometry
5 Diffraction of Radiation X-ray, electron Diffraction methods.
6 Rotation of Radiation Polarimetry
7 Electrical Potential Potentiometry
8 Electrical Conductance Conductometry
9 Electrical Current Polarography, Amperometric titrations
10 Mass-to-charge ratio Mass spectrometry
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It involves the measurement of the absorbance of a sample solution and of a standard
solution of the reference substance. The concentration of the substance in the sample
is calculated from the proportional relationship that exists between absorbance and
concentration.
                                             Atest× Cstd
                                Ctest =
                                                Astd
Cstd = Concentration of the standard solution 
Ctest =   Concentration of the sample
Atest and Astd = Absorbances of the sample and standard solutions.
b) Calibration graph method
In  this  procedure  the  absorbances  of  a  number  of  standard  solutions  of  the
reference  substance  at  concentrations  encompassing  the  sample  concentrations  are
measured and a calibration graph is constructed. The concentration of the analyte in the
sample  solution  is  read  from  the  graph  as  the  concentration  corresponding  to  the
absorbance of the solution.
Assay of Multi-Component samples: 
The assay of components of mixture sample can be done by following methods:
1)   Simultaneous Equation method
2) Absorbance Ratio method
3) Geometric Correction method
4) Difference spectrophotometry
5) Derivative spectrophotometry
The basis of all the spectrophotometric techniques for multicomponent samples
is the property that at all wavelengths,
a) The  absorbance  of  a  solution  is  the  sum  of  absorbances  f  the  individual
components or
b) The measured absorbance is the difference between the total absorbance of the
solution in the sample cell and that of the solution in the reference (blank) cell.
Simultaneous Equation method
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 If a sample contains two absorbing drugs (X and Y) each of which absorbs at
the λmax of the other, it may be possible to determine both drugs by the technique of
simultaneous equation.
The information required is:
a) The absorptivities of X at λ1 and λ2, ax1 and ax2 respectively.
b) The absorptivities of Y at λ1 and λ2, ay1 and ay2 respectively.
c) The absorbances of the diluted sample at λ1 and λ2, A1 and A2 respectively.
d) Let Cx and Cy be the concentrations of X and Y respectively in the diluted sample.
  Two equation  are  constructed  based  upon  the  fact  that  the  sum of     individual
absorbance of X and Y.            
                    At λ1, A1= ax1bcx+ay1bcy
                    At λ2, A2= ax2bcx+ay2bcy
                              A2ay1 – A1ay2
 Cx =
                             ax2ay1 – ax1ay2
  A1ax2 – A2ax1
 Cy =
                              ax2ay1 – ax1ay2
     Using the above equations, concentrations of individual components in a mixture
can be determined.           
Difference spectrophotometry
The  selectivity  and  accuracy  of  spectrophotometric  analysis  of  samples
containing  absorbing  interferents  may  be  markedly  improved  by  the  technique  of
difference spectrophotometry.
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The  essential  feature  of  a  difference  spectrophotometric  assay  is  that  the
measured value is the difference absorbance (∆A) between two equimolar solutions of
the analyte in different spectral characteristics.
The criteria for applying spectrophotometry to the assay of a substance in the
presence of other absorbing substances are that:-
a) Reproducible changes may be induced in the spectrum of the analyte by the addition
of one or more reagents.
b) The absorbance of the interfering substances is not altered by the reagents.
Derivative Spectrophotometry
Derivative Spectrophotometry involves the conversion of a normal spectrum to its first,
second or higher derivative spectrum. The transformations that occur in the derivative
spectra are understood by the reference to a Gaussian band which represents an ideal
absorption band.
The first derivative (D1) spectrum is a plot of the rate of change of absorbance
with wavelength against wavelength i.e. a plot of the slope of fundamental spectrum
against wavelength or a plot of δA δλ Vs λ.
The second derivative (D2) spectrum is a plot of the curvature of the D0  (Zero
order spectrum) against wavelength or a plot of δ2A δ2λ Vs λ.                             
The  spectral  transformations  confer  two  principle  advantages  on  derivative
spectrophotometry.
1)  An  even  order  spectrum  is  of  narrow  spectral  bandwidth  than  its  fundamental
spectrum.
2) Derivative spectrophotometry discriminates in favour of substance of narrow spectral
bandwidth against broad bandwidth substances.
Hence  substance  of  narrow  spectral  bandwidth  displays  larger  derivatives,
amplitudes than those of broad bandwidth substances.
Absorbance Ratio Method
The absorbance ratio method is a modification of the simultaneous equations
procedure. It depends on the property that, for a substance which obeys Beers law at all
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wavelength,  the  ratio  of  absorbances  at  any  two  wavelengths  is  a  constant  value
independent of concentration or path length.
Here absorbances are measured at two wavelengths one being the λ of one of the
components (λ2 ) and the other being a wavelength of equal absorptivity of the two
components (λ1), i.e. an iso-absorptive point. 
1.2. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
Chromatography is the separation of a mixture into individual components using
a stationary and mobile phase. Early liquid chromatography was carried out in glass
columns with diameters of 1 to 5 cm and lengths of 50 to 500 cm. The average diameter
of the solid stationary phase  particles  was usually in the  100 to 200 micron range.
Recent technology has allowed for the development of packing material with relatively
small particle size diameter (3-10 micron). This technology resulted in the development
of columns with very high efficiencies, and consequently has involved the use of more
sophisticated instrumentation to  perform at  increased pressure and flows; Hence the
term High Performance Liquid chromatography (HPLC).
The typical HPLC separation is based on the selective distribution of analytes
between a liquid mobile phase and an immiscible stationary phase. The sample is first
introduced by means of an injection port into the mobile phase stream that is delivered
by a high-pressure pump. Next, the components of this sample mixture are separated on
the  column,  a  process  monitored  with  a  flow-through  detector  as  the  isolated
components emerge from the column.
The  method  is  popular  because  it  is  non-destructive  and  may be  applied  to
thermally labile compounds (unlike GC); it is also a very sensitive technique since it
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incorporates  a  wide  choice  of  detection  methods.  With  the  use  of  Post-column
derivatization methods to improve selectivity and detection limits, HPLC can easily be
extended to trace determination of  compounds that  do not usually provide adequate
detector response. The wide applicability of HPLC as a separation method makes it a
valuable separation tool in many scientific tools.               
1.2.1. Parameters used in Chromatographic Characterization
Retention:  The retention of a drug with a given packing material and eluent can be
expressed as retention time or retention volume, but both of this are dependent on flow
rate, column length and column diameter.  The retention is best described as a column
capacity ratio (K), which is independent of these factors.  The column capacity ratio of
a compound (A) is defined as
   VAV0                 tA-t0
       KA = = 
                                          V0                               t0
Where,
VA =  Elution volume of A 
V0 = Elution volume of a non retained compound (void volume)
At constant flow rate, retention times (tA and to) can be used instead of retention
volumes. 
Retention data is sometimes expressed, relative to a known internal standard (B).
The ratio of retention times (tA/tB) can be used, but the ratio of adjusted retention times
is better when data need to be transferred between different chromatographs.  
Resolution:  The  distance  between  any  two  adjacent  peaks  in  a  multi  peak
chromatogram is referred to as Resolution ‘Rs’ and is calculated as 
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2(t2-t1)
                                      R=    
                                              W1 + W2
Where,
t1 and t2 are the retention times for the latest and the earliest eluting peak and W1 and
W2, are the peak width at baseline.
R≥1 = Components completely separated 
R≤1 = Components overlap.
Capacity Factor (K1) -  The retention of the analyte expressed as the number of void
volumes of the system, needed for the peak to elute is called the capacity factor.  The
expression for K1 is
                                          tr -t0
K1=   
                                           t0
Where,
tr = retention time
t0 = void volume 
Theoretical plates (N)
The number  of  theoretical  plates  generated  on a  column is  a  measure  of  its
performance.  The definition of N is 
Where, 
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tr = retention time 
W = peak width 
‘N’ may also be calculated from the width along the baseline of the peak.
This is accomplished by extending tangents from the two peak inflection points
through the baseline.
Separation factor ()
This  parameter  is  used  to  quantify  the  separation  between  adjacent  peaks.
Ideally, the peaks should not overlap, that is they should be baseline resolved.  This
condition is meant for peaks of similar size when  > 1.15.  The separation factor is
calculated as follows.
                                             K12
                                   =   
                                             K11
Where,
The subscripts refer to the order of elution.  is always ≥1.
Asymmetry – The asymmetry is a tool for quickly determining how much if any, of an
eluting peak profile deviates in shape from a normal distribution.  The subscripts  ‘X’
refer to the percentage of peak height at which the asymmetry is determined. 
Eg: A10 (determined at 10% peak height)
The equation for determining peak asymmetry is 
                                         AX=b/a,
Where,
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‘b’ =   The distance between the perpendicular connecting the baseline  to
peak maximum and the latest eluting portion of the curve.
‘a’ =   The distance between the perpendicular connecting the baseline  to  the  peak
maximum and the earliest eluting portion of the curve.
1.4. METHOD VALIDATION
Method  validation  is  the  process  to  confirm  that  the  analytical  procedure
employed  for  a  specific  test  is  suitable  for  its  intended  use.  Methods  need  to  be
validated or revalidated,
 Before their introduction into routine use 
 Whenever  the  conditions  change  for  which  the  method  has  been  validated,  e.g.,
instrument with different characteristics.
 Whenever the method is changed, and the change is outside the original scope of the
method.
The  International  Conference  on  Harmonization  (ICH)  of  Technical
Requirements for the Registration of Pharmaceuticals for Human Use has developed a
consensus  text  on  the  validation  of  analytical  procedures.  The  document  includes
definitions for eight validation characteristics.
The parameters as defined by the ICH and by other organizations
• Specificity 
• Selectivity
• Precision 
Repeatability 
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 Intermediate precision 
 Reproducibility 
• Accuracy 
• Linearity 
• Range 
• Limit of detection 
• Limit of quantitation 
• Robustness 
• Ruggedness
SPECIFICITY
Specificity is the ability to assess unequivocally the analyte in the presence of
components that may be expected to be present. 
A specific method can accurately measure the analyte of  interest  even in the
presence of potential sample components (placebo ingredients, impurities, degradation
products etc.)  When criteria for specificity are not met,  this  often indicates that the
method is not sufficiently developed; furthermore, it is likely that criteria for accuracy,
precision,  and linearity may also not be  fulfilled.  A major  objective  of  determining
specificity is to ensure “peak purity” of the main compound to be determined, in other
words, confirm that no related compound or product ingredient co elutes and interferes
with the measurement of the assayed compound.
PRECISION
The precision of an analytical procedure expresses the closeness of agreement
between a series of measurements from multiple sampling of the same homogeneous
sample under prescribed conditions. Precision may be considered at three levels:
   Repeatability
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   Intermediate precision 
   Reproducibility 
1) Repeatability
Repeatability expresses the precision under the same operating conditions over a
short interval of time.
Repeatability of a method can be determined by multiple replicate preparations
of the same sample. This can be done either by multiple sample preparation (n = 6) in
the same experiment or by preparing 3 replicates at 3 different concentrations.
2) Intermediate Precision
Intermediate precision expresses within laboratories variations: Different days,
different analysts, different equipments etc.
3) Reproducibility
Reproducibility expresses the precision between laboratories.  This  is  optional
validation parameter that requires demonstration of laboratory - to - laboratory variation
only if multiple laboratories use the same procedure. 
ACCURACY
The accuracy of an analytical procedure expresses the closeness of agreement
between the value which is accepted either as a conventional true value or an accepted
reference value and the value found. 
Accuracy is  often  determined  by recovery studies  in  which  the  analytes  are
spiked  into  a  solution  containing  the  matrix.  The  matrix  (placebo  in  formulations)
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should be found not to interfere with the assay of the compound(s) of interest. 
LINEARITY
The linearity of an analytical procedure is its ability (within a given range) to
obtain test results which are directly proportional to the concentration (amount) of the
analyte in the sample. 
Different Approaches for linearity determination.
ii) The first approach is to weigh different amounts of authentic sample
directly to prepare linearity solutions of different concentrations. 
ii) Another  approach  is  to  prepare  a  stock  solution  of  high  concentration,  then
perform serial  dilution  from  the  stock  solution  to  obtain  solutions  of  lower
concentrations for linearity determination. 
RANGE
The range of an analytical procedure is the interval between the upper and lower
concentration (amounts) of the analyte in the sample (including these concentrations)
for  which  it  has  been  shown  that  the  analytical  procedure  has  a  suitable  level  of
precision, accuracy and linearity.
LOD AND LOQ
Detection limit (LOD)
The detection limit of an individual analytical procedure is the lowest amount of
analyte in a sample which can be detected but not necessarily quantitated as an exact
value. In chromatography detection limit is the injected amount that results in a peak
with a height at least twice as high or thrice as high as baseline noise level.
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                                        S/N = 2/1 or 3/1
Quantitation limit (LOQ)
The quantitation limit of an individual analytical procedure is the lowest amount
of analyte in a sample which can be quantitatively determined with suitable precision
and accuracy. In chromatography, quantitation limit is the injected amount that results
in a peak with a height ten times as high as baseline noise level.                                 
           S/N = 10/1
Different approaches to determine LOD and LOQ
1. Signal to noise approach
Quatitation limit at each concentration = 
10 x
Concentration ( in related subs tan ce )
S /N ( average at each concentration)
2. Standard deviation approach
QL = 10 x 
SD
S DL = 3.3 x 
SD
S
SD = Standard deviation of the response near QL 
S = Slope of the linearity curve near QL
ROBUSTNESS
The  robustness  of  an  analytical  procedure  is  the  measure  of  its  capacity  to
remain  unaffected  by  small,  but  deliberate,  variations,  in  method  parameters  and
provide an indication of its reliability during normal usage. This is to verify that the
method  performance  is  not  affected  by  typical  changes  in  normal  experiments.
Therefore, the variation in method conditions for robustness should be small and reflect
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typical day to day variation.
RUGGEDNESS
The United  States Pharmacopoeia (USP) define ruggedness as the degree of
reproducibility of test results obtained by the analysis  of the same samples under a
variety of normal test conditions, such as different labs, different analysts, different lots
of reagents etc. Ruggedness is a measure of reproducibility of test results under normal,
expected  operational  conditions  from  laboratory  to  laboratory  and  from  analyst  to
analyst.
2. NEED FOR THE STUDY 
      According to WHO, a drug may be defined as any substance or product that is used
or  intended  to  be  used  for  modifying  or  exploring  physiochemical  systems  or
pathophysiological stages for the benefit of the patient. Pharmaceutical Chemistry is a
science  that  makes  use  of  general  laws  of  chemistry  to  study  drugs  i.e.,  their
preparation, chemical natures, composition, structure, influence on an organism. It also
studies the physical and chemical properties of drugs, the methods of quality control
and the conditions of their storage etc. The family of drugs may be broadly classified as
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     1. Pharmacodynamic agents and
2. Chemotherapeutic agents
      We use drugs almost every single day. The quality of the drug is the most essential
feature and that parameter directly affects the life of the customer. The quality of any
product  or  material  can  be  judged  by only analysing  it.  It  is  necessary to  find  the
content  of  each drug either  in  bulk or  single  or  combined  dosage forms for  purity
testing. It is also essential to know the concentration of the drug and it’s metabolites in
biological fluids after taking the dosage form for treatment. The scope of developing
and validating an analytical  method is  to  ensure  a procedure  which is  specific  and
accurate for a particular analyte. The primary objective is to improve the conditions and
parameters to be followed in the method development and validation.
         The review of literature revealed that several methods are available for the
determination  of  Acebrophylline  and  Montelukast  sodium  individually.  Reported
method  for  estimation  Acebrophylline  in  dosage  form  are  spectrophotometry,  RP-
HPLC, and HPTLC and similarly for estimation of Montelukast sodium in dosage form
are spectrophotometry, spectrofluorimetry, Voltametric, RP-HPLC and HPTLC. 
But, there is no any analytical method has been reported yet for combination of these
drugs. There for the present research work aims to develop a simple, sensitive, accurate
and  reproducible  method  for  simultaneous  estimation  of  Acebrophylline  and
Montelukast sodium in combined dosage form by spectrophotometric method   
2.2 OBJECTIVES
Following are the objectives of present work
  To perform method development for the drugs
  To study effect of various mobile phases used in method development
  To determine the drug content in given pharmaceutical dosage form
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  To validate analytical methods as per ICH guidelines 
  To demonstrate that it is suitable for its intended purpose
  To establish identity, detect and quantitated impurities and to assess characteristics
Following parameters according to ICH Guidelines to be validated
   Specificity
 Linearity
 Range  
 Accuracy
 Precision
   Limit of  Detection
   Limit of Quantification
   Robustness   
3.LITERATURE REVIEW
1. Bhagavati Solanki Bhagavati Solanki, Harshal Trivedi, Ankita Khodiyar, Falguni
Tandel,  Lalit  Lata  Jha,  Rajesh  KS [13],  developed  Derivative  Spectroscopic
Method For Estimation of Acebrophylline In Bulk And Its Dosage Form & In
Presence of Impurity, Ambroxol HCl.  A sensitive, selective and validated first
derivative spectrophotometric method using methanol have been proposed for
the  determination  of  Acebrophylline  which  is  widely  used  as  anti  asthmatic
agent. The method is accurate, precise and linear over a range of 5-50µg/ml for
Acebrophylline. The limit of detection was observed as 0.178µg /ml, the limit of
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quantification  was  observed  as  0.598µg/ml.  The  %RSD  is  less  than  2%  in
methanol. Method accurately estimates Acebrophylline in presence of Ambroxol
with 99-100% recovery. The method can be applied for Acebrophylline tablet
formulation with 99-100% recovery.
2. Sunil R Dhaneshwar, Vaijanath N. Jagtap [14], had developed stability-indicating
RP-HPLC-PDA method  and  subsequently  validated  for  the  determination  of
Acebrophylline  in commercial  capsules.  The proposed HPLC method utilizes
waters  Cosmogel  C18 column (150  mm x  4.6  mm,  5.0  µ  particle  size)  and
mobile phase consisting of methanol:acetate buffer (20:80 v/v) pH adjusted to 6
with  glacial  acetic  acid  at  a  flow  rate  of  0.85  mL/min  and  column  was
maintained at 500 C. Quantitation was achieved with UV detection at 274 nm
based on peak area with linear calibration curves at concentration ranges 0.5-200
µg/mL for ACB (R2 > 0.999). ACB and its drug products were exposed to acid,
base  and  neutral  hydrolysis,  oxidation,  heat  and  photolytic  stress  conditions.
Under all these conditions, degraded products were well separated. The method
was  validated  according  to  the  ICH  guidelines  with  respect  to  accuracy,
precision,  linearity,  specificity,  limits  of  detection,  limits  of  Quantitation  and
robustness. 
3. Uday  D  Thesia  et  al[15]   developed  First  order,  Area  under  curve  and  dual
wavelength  Spectrophotometric  methods   for  simultaneous  estimation  of
Montelukast  sodium and  Acebrophylline  in  bulk  drug  and  in  pharmaceutical
formulation.  All  these  methods  utilizes  methanol  as  a  solvent.  In  First  order
spectroscopy 236.4nm and 334.4nm were selected as ZCP (zero crossing point)
for determination of both the drugs simultaneously.  In Area Under Curve the
wavelength ranges of 277-287 nm and 270-280 nm were selected as analytical
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wavelength ranges for the determination of area of both the drugs in pure and in
combined formulation. In Dual wavelength method, the absorbance difference
was  determined  within  244nm  and  254nm  for  the  the  determination  of
Montelukast sodium, and absorbance difference within 265nm and 285nm for
the determination of Acebrophylline. The results of analysis of all methods have
been validated statistically. Lower value of % RSD indicates that these methods
were simple,  rapid  and accurate,  hence can be used for routine simultaneous
estimation of these drugs in formulations. 
4. Ravisanker M, Uthirapathy S et al[16], developed and validated RP-HPLC method
for  simultaneous  estimation  of  Fexofenadine  hydrochloride  and  Montelukast
sodium  in  bulk  drug  and  marketed  formulation,  using  water  symmetry  C8
column.  The  mobile  phase  consisted  of  0.05M  potassium  dihydrogen
orthophosphate and Acetonitrile in the ratio of 35:65% v/v (pH 
6 with TEA). The flow rate was kept at 1.0ml/min and the wavelength selected
for the Quantitation was 226 nm. The retention time was found to be 2.127 min
for  Fexofenadine  and  5.650  min  for  Montelukast  sodium.  The  linearity  was
found to be in the range of 4.8-28.8 µg/ml and 0.4-2.4 µg /ml for Fexofenadine
and Montelukast respectively with the correlation coefficient of 0.999. The mean
recoveries  for  Fexofenadine  and  Montelukast  were  observed  as  99.85% and
100.19% respectively,  and relative  standard deviation  was less  than 2%. The
assay value for Fexofenadine and Montelukast were found to be 100.55% and
100.40% respectively.
5. Konam K, Hariprasad P, Lukaraju PS, Sirajudeen MA, Fareedullah MD, Ahmed
I [17]  had developed and validated high-performance thin-layer chromatographic
method  for  the  estimation  of  Montelukast  sodium  and  Levocetirizine
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hydrochloride  simultaneously  in  combined  dosage  form.  In  this  method
stationary phase used was precoated silica gel 60F 254 and mobile phase used
was a mixture of Chloroform: Benzene: Methanol:  Toluene (5:7.2:1:0.2).  The
detection of spots was carried out at 286nm. The calibration curve was found to
be  linear  between  500-1500ng/spot  for  Montelukast  sodium  and  1000-
5000ng/spot for Levocetirizine hydrochloride.
6. Kumar  BVVS,  Mathur  P,  Rajesh  N,  Rao  ND,  Satyanarayana  P  [18]     had
developed and validated reversed phase HPLC method for the determination of
Levocetirizine hydrochloride and Montelukast sodium in pharmaceutical dosage
forms using C8 column [4.6 x 150mm, 3.5mm, Make: XTerra] with a mobile
phase of potassium di hydrogen 
orthophosphate buffer and acetonitrile (60:40 v/v) at a flow rate of 0.8ml/min
and detection was carried out at 230nm. The retention time of Levocetirizine
hydrochloride and Montelukast sodium was found to be 2.432 min and 6.218
min respectively.  The method was observed to  be linear in the concentration
range  of  30-70µg/ml for  both  the  drugs.  The  LOD values  were  found  to  be
3.36ng/ml  and  3.20ng/ml  and  the  LOQ  were  9.90ng/ml  and  9.86ng/ml  for
Levocetirizine hydrochloride  and Montelukast  sodium respectively.  The mean
recoveries  were  found  to  be  100.2%  and  99.7%  for  Levocetirizine
dihydrochloride and Montelukast     sodium, respectively.
7. Patel  NK,  Pancholi  SS  [19] had  developed  spectrophotometric  method  for
Montelukast sodium and Levocetirizine dihydrochloride in tablet dosage form by
AUC  curve  method.  The  area  under  curve  was  selected  from  263.6nm  to
293.6nm and 222nm to 242nm for determination of Montelukast  sodium and
Levocetirizine dihydrochloride respectively. Both drugs showed linearity in the
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concentration range of  5-30µg/ml.  The limit  of  detection (LOD) and limit  of
quantification (LOQ) were determined by visual methods as suggested in ICH
guidelines,  which  were  found  to  be  1.6µg/ml  and  4.8µg/ml  at  222-242nm,
1.06µg/ml and 3.1µg/ml at 263.6-293.6nm for Montelukast sodium respectively.
The  LOD  and  LOQ  were  1.23µg/ml  and  3.71µg/ml  at  222-242nm  for
Levocetirizine dihydrochloride respectively. The % assay results were found to
be 98.90 ± 0.61% for Montelukast sodium and 98.75 ± 0.96% for Levocetirizine
dihydrochloride of the labeled claim. The result of recovery studies were found
to be in the range of 97.87-98.95% and 98.63-99.68% for Montelukast sodium
and Levocetirizine dihydrochloride, respectively.
8. Choudhari  V, Kale A, Abnawe A, Kuchekar B, Gawli A, Patil N[20]       had
developed  ratio  derivative  spectrophotometric  method  for  the  simultaneous
determination  of  Montelukast  sodium  and  Levocetirizine  dihydrochloride  in
pharmaceutical  preparations.  This  method  involved  measurement  of  first
derivative amplitude of ratio spectra at 250.4nm for Montelukast  sodium and
238.4nm for Levocetirizine dihydrochloride as two wavelengths for estimation.
Beer's law was obeyed in the concentration range of 4-12µg/ml and 2-6µg/ml for
Montelukast  sodium  and  Levocetirizine  dihydrochloride  respectively.  LOD
values were found to be 0.09µg/ml and 0.178µg/ml and the  LOQ values  are
found  to  be  0.277µg/ml  and  0.591µg/ml  for  Montelukast  sodium  and
Levocetirizine  dihydrochloride  respectively.  The  %  assay  was  found  to  be
96.86% for Montelukast sodium and 99.63% for Levocetirizine dihydrochloride.
Results of recovery studies were found to be in the range of 99.79%-100.68%
with % RSD values ranging from 0.394%-0.777% for Montelukast sodium and
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99.44% to 100.2%, with % RSD values ranging from 0.425% to 0.808% for
Levocetirizine dihydrochloride.
9. Alsarra  I,  AI-Omer  M,  Gadkariem  EA and  Belal  F  [21], studied  voltametric
determination of montelukast sodium in pharmaceutical dosage form and human
plasma.  The voltametric  behavior  of  Montelukast  was observed using Cyclic
voltametry  Direct  current  (DCt),  Differential  Pulse  Polarography  (DPP)  and
Alternating  Current  (ACt)  polarography.   Montelukast  exhibited  well  defend
cathodic waves over the pH range of 1-5. No anodic waves were produced over
the same pH range at pH 1, the
 analytical pH: the diffusion current constant (Id) was 2.2 ± 0.01µAI/ mol. The
current concentration plot was found rectilinear over the range 2-20µg/ml with
correlation coefficient (n=10) of 0.9943. The lower limit of detection (S/N= 2)
was  found  at  0.2µg/ml  (3.41×10-7M)  .The  wave  had  characterized  as  being
diffusion controlled. Although adsorption phenomenon played a limited role in
the electrode reaction.
10. Radhakrishna T, Narsaraju A, Ramakrishna M, Satyanarayna A[22]     developed
and validated HPLC and second order derivative spectrophotometric method for
simultaneous  estimation  of  Montelukast  and  Loratadine  from pharmaceutical
formulation. HPLC separation was achieved with a symmetry C18 column and
sodium phosphate buffer (pH adjusted to 3.7): Acetonitrile (20:80 %v/v) as elute,
at  a  flow rate  of  1.0 ml/min and UV detection was performed at  225nm. 5-
Methyl  2-nitrophenol  was  used  as  an  internal  standard.  In  the  second  order
derivative  spectrophotometry  ,  for  the  determination  of  Loratadine  the  zero
crossing technique was applied at 276.1 
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nm, and for Montelukast peak amplitude at 359.7 nm (tangent method) was used.
The  percentage  recovery  was  found  in  the  range  of  99.05-100.47  for
Montelukast  and  99.00-100.02  for  Loratadine  by  HPLC  method  and  98.43-
101.62  for  Montelukast  and 98.41-100.98%  for  Loratadine  by second order
derivative method.
11. J  Maniya,  H  Raj,  K  Muralikrishna,  P  Lakshmi,  B  Khanpara,  V  Shelar  [23]
developed   and  validated  reversed  phase  high-performance  liquid
chromatographic   method.  The  method  was  performed  on  Unisphere  C18
column (250mm X 4.6 mm i.d., 5 µm particle size) at 40oC; the mobile 
phase, consisting of a mixture of Sodium acetate (200mM, pH adjusted to 6 with
glacial acetic acid) : Methanol : Acetonitrile (20:30:50 v/v/v) was delivered at a
flow rate of 1.0mL/min and detector wavelength at 272 nm. The retention time
of Theophylline-7-acetate and Ambroxol  was found to be 2.22 and 4.52 min
respectively as  an individual  component  of  Acebrophylline  and 5.22 min  for
Montelukast sodium. Linearity ranges were 100-600 and 5-30 µg/ ml with limit
of detection values of 0.52 and 0.05µg/ml for Acebrophylline and Montelukast
sodium respectively. In First order derivative spectroscopy method, absorbance
of Acebrophylline was measured at 282 nm (Zero Crossing Point of Montelukast
sodium) and absorbance of Montelukast sodium was measured at 368 nm (Zero
Crossing  Point  of  AcebrophyllineResults  of  assay and  recovery studies  were
statistically evaluated for its accuracy and precision. Correlation coefficients (r2)
of the regression equations were greater than 0.999 in all cases
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4.AIM AND OBJECTIVE OF WORK
2.1 AIM OF WORK:
The  scope  of  developing  and  validating  a  method  is  to  ensure  a suitable  strategy
for a particular analyte which is more stable ,cheap specific accurate  precise, and  less
time consumingfor the simultaneous estimation of  Acebrophylline  and Montelukast in
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tablet dosage form and validate as per ICH guidelines. The existing available literature
reveals that there are no available analytical methods for simultaneous estimation of
Acebrophylline and Montelukast.
Hence attempt  is  being made to develop sensitive,  simple,  accurate  and robust  RP-
HPLC method for simultaneous estimation of Acebrophylline and Montelukast in bulk
and  tablet  dosage  form.  And  to  validate  the  developed  method  by establishing  the
parameters like accuracy, precision, linearity, LOD, LOQ, robustness.
The plan of work is as follows:
i) Study  of  physicochemical  properties  of  drug,  (pH,  pKa,  solubility  and
molecular weight)
ii) Preparation of drug standard and sample, 
iii) Simultaneous  estimation  of  Acebrophylline  and  Montelukast  sodium from
formulation by UV spectrophotometric method using Simultaneous Equation
Method 
iv) Optimization chromatographic conditions like,
a. Selection of wavelength
b. Selection of initial separation conditions
c. Nature of stationary phase 
d. Nature of mobile phase (pH, solvent strength, solvent ratio and flow rate)
v) Study of system suitability parameters,
vi) Validation of proposed method by RP-HPLC.
vii) Applying developed method to marketed formulation.
Page 29 of 86
5. DRUG PROFILE
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MONTELUKAST
Structure
Molecular formula C35H36ClNO3S
Molecular weight 586.183
Chemical IUPAC
Name
2-[1-({[(1R)-1-{03-[(E)-2-(7-chloroquinolin-2-
yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-
yl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]acetic
acid
Solubility Freely soluble in ethanol, methanol and water Insolublein acetonitrile.
Category
• Anti-Asthmatic Agents
• Antiarrhythmic Agents
• Leukotriene Antagonists
Class
• Phenylpropenes
• Cumenes and Derivatives
• (Iso)quinolines and Derivatives
Available dosage form Tablets
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ACEBROPHYLLINE
Structure
Molecular formula C22H28Br2N6O5
Molecular weight 616.30
Chemical IUPAC Name
1,2,3,6-Tetrahydro-1,3-dimethyl-2,6-dioxo-7H-
purine-7-acetic acid with trans-4-[[(2-Amino-3,5-
dibromophenyl)methyl]amino]cyclohexanol
Solubility Freely soluble in water, ethanol. Insoluble indiethyl ether, Acetonitrile.
Category Mucolytic – Bronchodilator
Class Anthocyanidins. (Iso)flavones and Derivatives
Available dosage form
Tablet.
Brand Name
Surfolase
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Brand name of Acebrophylline and Montelukast sodium Hydrochloride:
ABROFYL-M (Manufacturer: Alkem laboratories ,( Mumbai )
Drug Dose
Acebrophylline 200mg
Montelukast sodium
Hydrochloride
10mg
Combination of Acebrophylline and Montelukast sodium hydrochloride
Acebrophylline and Montelukast sodium Hydrochloride is available in combined
dosage forms as film coated tablets (ABROFYL-M). Each tablet contains 200mg of
Acebrophylline and 100 mg of Montelukast sodium Hydrochloride. It is used for the
treatment of Respiratory Tract Infection. Acebrophylline (ACBR) , 1,2,3,6-tetrahydro-
1,3-dimethyl-2,6-dioxo-7H-Purine-7-aceticacid  compd.  with  trans-4-[[(2-amino-3,5-
dibromophenyl)methyl]amino]cyclohexanol  is  the  salt  obtained  by  reaction  of
equimolar  amounts of theophylline-7-acetic acid,  a xanthine derivative with  specific
bronchodilator  activity  and  ambroxol,  a  Mucolytic  and  expectorant.  Montelukast
sodium (MTKT), [R-(E)]-1 -[[[1-[3-[2-(7-chloro 2quinolinyl) ethenyl] phenyl]-3-[2-(1-
hydroxy-1  methylethyl)  phenyl]  propyl]  thio]  methyl]  cyclopropane  acetic  acid,
monosodium salt  is a selective and orally active leukotriene receptor antagonist that
inhibits the cysteinyl leukotriene CysLT1 receptor. By blocking Leukotrienes, improves
asthma symptoms, help to control  asthma and improves seasonal allergy symptoms.
The combination of these two drugs are available in the market for the treatment of
chronic obstructive pulmonary disease (COPD) and bronchial asthma and also clinical
trials has been reported for this combination in India.
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6.  MATERIALS AND INSTRUMENTS
a) Pure drug samples
Both  the  drug  samples  of  Acebrophylline  and  Montelukast  Sodium  were
received as a gift samples from AMIS Pharmaceuticals -Vadodhara and Dr. MACS BIO
PHARMA., Hyderabad respectively.
b) Chemicals and solvents used
 Methanol: HPLC grade, Qualigens Fine Chemicals, Mumbai.
 HPLC water: Qualigens Fine Chemicals, Mumbai.         
 Orthophosphoric acid  :88% GR, Merck, Mumbai.                             
 Triethylamine:  S.D. Fine Chemicals Ltd.,   Mumbai.
c) Instruments
 Schimadzu Digital Electronic Balance- BL 220H.
 Lab India SAB 5000, pH meter.
 Value Vacuum pump.
 Schimadzu UV-1800, UV/Vis-Spectrophotometer.
 Schimadzu HPLC, BDS Hypersil C18 column, UV detector.
 Ultrasonic cleaner, Life care equipmentspvt.ltd. 
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                           Fig: 6.1. UV-Visible Spectrophotometer
 Fig: 6.2. High Performance Liquid Chromatography (HPLC)
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Fig: 6.3. pH Meter
Fig: 6.4. Value 1 stage, Vacuum pump
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Fig: 6.5. Shimadzu Digital Electronic Balance – BL 220H
Fig: 6.6. Fast clean Ultrasonicator
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7. METHODOLOGY
7 .1 DEVELOPMENT AND VALIDATION OF UV SPECTROSCOPIC METHODFOR
SIMULTANEOUS  ESTIMATION  OF  ACEBROPHYLLINE  AND  MONTELUKAST
SODIUMIN  COMBINED  DOSAGE  FORMS  BY  SIMULTANEOUS  EQUATION
METHOD
7.1.1. Selection of solvent
Solutions of Acebrophylline and Montelukast Sodium were prepared in different
solvents like methanol, ethanol, acetonitrile and UV spectrum of each were recorded by
scanning between 200-400 nm.
An  overlain  spectrum  of  Acebrophylline  and  Montelukast  were  prepared  in
different  solvents like methanol,  ethanol etc.,.  Better  absorbances were observed for
both the drugs when ethanol is used as a solvent as shown in the figure 7.11. Hence,
ethanol was selected as solvent for present study. 
From the spectra of drugs in ethanol, four trial wavelengths were selected (250,
273,296  and  315nm)  for  their  simultaneous  estimation.  Different  concentrations  of
Acebrophylline(6  to  24µg/ml),  Montelukast  (  6  to  24µg/ml)  and  mixture  of
Acebrophylline and Montelukast were prepared, scanned and absorbances were noted at
these three wavelengths.From these data, it was noted that, at the wavelengths 250 and
273 nm, good linearity was observed and hence these wavelengths were fixed for the
study.
Page 38 of 86
Fig: 7.1.1: Overlain Normal spectra of Acebrophylline and Montelukastin ethanol
                           7.1.2. VALIDATION OF THE METHOD
LINEARITY
Acebrophylline
Acebrophylline was found to be linear in a concentration range of  6-24µg/ml.
The  absorbances  of  these  solutions  were  noted  at  wavelengths  250  and  273  nm,
respectively.  Calibration  curves  were  plotted  using  concentration  Vs  absorbance  at
wavelength of  250nm and the slope, intercept and correlation coefficient values were
found  to  be  0.023,0.045,  and  0.998 respectively,  fig.  7.1.2.  At  wavelength  273nm,
slope,  intercept and correlation coefficient values were found to be  0.017,0.038 and
0.997 respectively, fig. 7.1.3.
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 Fig: 7.1.2: Calibration graph of Acebrophylline at 250nm
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Fig: 7.1.3: Calibration graph of Acebrophylline at 273nm
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Table: 7.1.1. Calibration data of Acebrophylline at 250nm and273nm
S. No
Concentration
(¬g/ml)
Absorbance at 250
nm
Absorbance at
273 nm
1 6 0.187 0.149
2 8 0.232 0.173
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3 10 0.289 0.211
4 12 0.332 0.243
5 14 0.366 0.271
6 16 0.417 0.307
7 18 0.469 0.345
8 20 0.516 0.381
9 22 0.555 0.408
10 24 0.621 0.459
MontelukastSodium:
Montelukast was found to be linear at a concentration range of 6-24µg/ml. The
absorbances of these solutions were noted at 250 and 273 nm, respectively. Calibration
curves were plotted using concentration Vs absorbance. At a wavelength of 250nm, the
slope, intercept and correlation coefficient values were found to be  0.032, 0.007 and
0.997 respectively, fig. 7.1.4.At wavelength 273 nm, the slope, intercept and correlation
coefficient values were found to be 0.040, 0.018and 0.997respectively,fig. 7.1.5.
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Fig: 7.1.4: Calibration graph of Montelukast at 250nm
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Fig: 7.1.5: Calibration graph of Montelukast at 273nm
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Table: 7.1.2. Calibration data of Montelukast at 250 and 273nm
S. No
Concentration
(µg/ml)
Absorbance at 250 nm
Absorbance at
273nm
1 6 0.205 0.271
2 8 0.248 0.325
3 10 0.325 0.422
4 12 0.397 0.513
5 14 0.451 0.584
6 16 0.525 0.676
7 18 0.603 0.774
8 20 0.645 0.831
9 22 0.704 0.910
10 24 0.769 0.983
PRECISION
Precision  studies  were  performed by preparing the  standards  three  times and
measuring the absorbances of drugs at 250 nm and 273 nm. Low RSD values indicate
that the method is precise. The values are shown in table 7.1.3 and 7.1.4.
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Table: 7.1.3. Intraday Precision studies
concentration
Absorbances %RSD*
Acebrophylline Montelukast Acebrophylline Montelukast
273
nm
250
nm
273
nm
250
nm
273
nm
250
nm
273
Nm
250
nm
10µg/ml
0.289 0.211 0.433 0.328
0.86 1.24
0.23 0.17
0.292 0.215 0.434 0.329
0.294 0.216 0.432 0.328
12µg/ml
0.332 0.243 0.515 0.389
0.46 0.82
0.11 0.14
0.334 0.245 0.515 0.388
0.335 0.247 0.516 0.389
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Table: 7.1.4. Inter day Precision studies
concentration
Absorbance %RSD*
Acebrophylline Montelukast Acebrophylline Montelukast
273
nm
250
nm
273
Nm
250
nm
273
nm
250
nm
273
Nm
250
nm
10µg/ml
0.289 0.211 0.433 0.328
1.07 0.96
0.35 1.41
0.285 0.209 0.430 0.328
0.283 0.207 0.432 0.320
12µg/ml
0.332 0.243 1.877 0.059
0.76 0.83
1.01 0.91
0.330 0.241 1.881 0.057
0.327 0.239 1.889 0.053
Recovery studies
In order to ensure the suitability and reliability of proposed method, recovery studies
were carried out. To an equivalent quantity of formulation powder (10mg), 9.5mg of
standard Montelukast sodium was added to it (standard addition method), so that the
sample  contains  10mg  each  of  Acebrophylline  and  Montelukast  Sodium  .  The  %
recovery and %RSD were calculated as shown below.
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Table: 7.1.5. Recovery studies
Level
%Recovery %RSD
Acebrophylline Montelukast Acebrophylline Montelukast
50% 98.33 98.5 0.1 0.27
100% 98.41 99.25 0.39 0.23
*RSD of three observations                                                            
7.1.3. ANALYSIS OF FORMULATION
Preparation of standard solutions
Standard  stock  solutions  of  Acebrophylline  and  Montelukast  were  prepared  by
dissolving 10 mg of the drug in  ethanol and the volume was made up to 100ml in a
standard flask. From the stock solution, concentrations ranging from 6-24µg/ml was
prepared for both Acebrophylline and Montelukast and scanned in the UV region. An
overlain spectrum of different concentrations of Acebrophylline and Montelukast and
mixture are shown in fig. 7.1.6-7.1.7.
Preparation of sample solution
Sample stock solution: 
Twenty tablets  (ABROFYL-M) each  containing  10  mg of  montelukast  sodium and
200mg  of  Acebrophylline  were  accurately  weighed  and  the  average  weight  was
calculated and finely powdered. A quantity equivalent to 9.5 mg of Montelukast sodium
was weighed and dissolved in ethanol  in 100ml volumetric flask (standard addition
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method).Sonicated to  dissolve it  completely and make volume up to the mark with
ethanol. Mixed well and filtered through 0.45µm filter to get the final 
concentration  of  100µg/ml.Finally  20mcg/ml  working  concentration  of  each  of
Acebrophylline and montelukast was prepared. Absorbances were noted at 250 nm and
273nm,  respectively,  fig.  7.1.8  and  table  7.1.6.  The  amounts  of  Acebrophyllineand
Montelukast were calculated using the simultaneous equation given below 
At µ1 A1 = ax1bcx + ay1bcy
λ2 A2 = ax2bcx + ay2bcy
C
fvx
=
A
2
ay
1
A
1
ay
2
ax
2
ay
1
ax
1
ay
2
C
ofx
=
A
1
ax
2
A
2
ax
1
ax
2
ay
1
ax
1
ay
2
A1 = absorbance of formulation at 250nm.
A2 = absorbance of formulation at 273nm.
ax1 = Absorptivity of Acebrophylline at 250nm.
ax2 = Absorptivity of Acebrophylline at 273nm.
ay1 = Absorptivity of Montelukast at 250nm.
ay2 = Absorptivity of Montelukast at 273nm.
Cfvx = Concentration of Acebrophylline. 
Cofx = Concentration of Montelukast.
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 Table: 7.1.6. Analysis of formulation
Drug
Amount (mg/tab)
% label claim % RSD*Labelled Found
Acebrophylline 200mg 199.8 99.90 0.53
Montelukast 10mg 10.2 102 1.37
*RSD of three observations
Fig: 7.1.6. Overlain UV spectra of Acebrophylline
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Fig: 7.1.7. Overlain UV spectra of Montelukast Sodium
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Fig: 7.1.8. UV spectra of formulation
(20µg/ml of Acebrophylline and 20µg/ml of Montelukast)
7.2  DEVELOPMENT  AND  VALIDATION  OF  RP-  HPLC  METHOD  FOR  THE
SIMULTANEOUS ESTIMATION OF ACEBROPHYLLINE AND MONTELUKAST IN
BULK ANDPHARMACEUTICAL DOSAGE FORM.
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7.2.1. Selection of chromatographic method for separation 
Reverse phase chromatographic technique is selected since both drugs are polar
in nature.
7.2.2. Selection of wavelength 
Sensitivity of HPLC method that uses ultraviolet (UV) detector depends upon
the proper selection of wavelength. An ideal wavelength is the one that gives maximum
absorbance and good response for the drug detected at lower concentration also.
From  the  UV  spectra  obtained  for  both  drugs,  250nm  was  selected  as  the
wavelength for study, fig. 7.2.1.
7.2.3. Initial chromatographic conditions: 
Selection of Mobile phase: 
For  developing  RP  –  HPLC  method,  different  mobile  phase  systems  with
different ratios were tried, among which 10mM phosphate buffer and Acetonitrile (pH
adjusted  to  4  using  1% Orthophosphoric  acid)  gave  symmetrical  peaks  with  good
resolution (Montelukast Rf – 6.7 minutes, Acebrophylline Rf – 3.6 minutes), and hence
fixed for further studies.
Different mobile phases were tried and their observations are given below in the
table.
Selection of Mobile Phase
S.no Mobile phase conditions Observation
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1. Water : Acetonitrile (30:70, v/v)
Tailing for Montelukast
and Acebrophylline peak
2.
10 mMphosphate buffer: acetonitrile
pH 8(30:70,v/v)
 Splitting of Montelukast
and Acebrophylline peak
3. 10 mM Phosphate buffer: acetonitrile
pH 6(30:70,v/v)
Good, symmetrical peaks
and less resolution.
4.
10 mM Phosphate buffer: acetonitrile
pH 4 (85:15,v/v)
Good, symmetrical peaks
and good resolution.
Chromatograms are shown in fig. 7.2.2-7.2.5.
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                        Fig: 7.2.1. UV spectra of Acebrophylline and Montelukast.
Selection of mobile phase
Fig: 7.2.2. Water and Acetonitrile (85:15)
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Fig:
7.2.3. 10mM phosphate buffer: Acetonitrile (85:15,v/v) pH 8
Fig:
7.2.4. 10mM phosphate buffer: Acetonitrile (85:15,v/v), pH 6
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Fig: 7.2.5. 10mM phosphate buffer: Acetonitrile (85:15,v/v), pH 4
7.2.4. OPTIMIZATION OF SEPARATION CONDITION
Selection of wavelength
Different wavelengths ie., 273nm, 250nm, 315nm were taken into consideration
from the  UV spectras  obtained.   The wavelength250nm was finally selected as  the
impurities were less intensified and the peak intensities were good.
Effect of ratio of mobile phase  
The  mobile  phase  system consisting  of  phosphate  buffer  and  acetonitrile  in
different  ratios  such  as  10:90,  30:70,  85:15  %  v/v,  adjusted  to  pH  4  using  1%
orthophosphoric acid were tried and the chromatograms were recorded at 250 nm at the
flow rate of 1 ml/min (fig. 7.2.9-7.2.10). The ratio of 85:15 % v/v, gave good separation
and symmetrical peaks and hence the ratio of 85:15% v/v was selected for the study.
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Ratio (% v/v) Retention time
10mM phosphate:ACN Acebrophylline Montelukast
10:90 4.08 10.2
15:85 3.6 6.7
30:70 3.0 2.8
Effect of pH
Keeping other conditions constant, chromatograms were recorded with different
pH such as 3,4,5,6 etc, adjusted using 1% orthophosphoric acid, fig. 7.2.11-
7.2.12.  At the pH of  4,  the peak shapes of  both drugs were good and hence
selected for further study.
pH Observation
3 Tailing of peaks
4 No tailing, Symmetrical peaks
5 Split peaks
6 Broad Split peaks
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Effect of strength of Phosphate buffer
Fig: 7.2.6. 30mM Phosphate buffer: Acetonitrile (15:85)
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Fig: 7.2.7. 20mM Phosphate buffer: Acetonitrile (15:85)
Fig:
7.2.8.10mM Phosphate buffer: Acetonitrile (15:85)
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Montelukast Sodium
Acebrophylline
Effect of ratio of mobile phase
 Fig: 7.2.9.10mMPhosphate buffer: Acetonitrile (10:90)
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Fig: 7.2.10.
10mM Phosphate buffer: Acetonitrile (15:85)
        Fig: 7.2.11.10mM Phosphate buffer: Acetonitrile (30:70)
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Effect of pH
      Fig: 7.2.12. 10 mM Phosphate buffer (pH 6): Acetonitrile (85:15)
   Fig: 7.2.13. 10 mM Phosphate buffer (pH 5): Acetonitrile (85:15)
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Fig: 7.2.14. 10 mM Phosphate buffer (pH 4): Acetonitrile (85:15)
  Fig: 7.2.15. 10 mM Phosphate buffer (pH 3): Acetonitrile (85:15)
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7.2.5. FIXED CHROMATOGRAPHIC CONDITIONS
Stationary Phase
BDS Hypersil, C18 Column,
(250 x 4.6mm , 5µ)
Mobile phase 10 mMphosphate buffer (pH 4): Acetonitrile
Solvent ratio 15:85
Detection wavelength 250 nm
Flow rate 1.0 ml/ml
Operating Pressure 60 kgf
Operating Temperature Room Temperature
Injection volume 20µl
Run time 10 min
Mode of operation Isocratic elution
 7.2.6. VALIDATION OF RP – HPLC METHOD
Limit of Detection (LOD) and Limit of Quantification (LOQ) 
LOD and LOQ of Acebrophylline and Montelukast  were calculated mathematically.
The LOD of Acebrophylline and Montelukast was found to be 0.087µg/ml and 0.010µg/ml.
The LOQ of Acebrophylline and Montelukast was found to be 0.289µg/ml and 0.033µg/ml
respectively 
Linearity and Range 
Acebrophylline and Montelukast  were found to  be linear  in  the  range  of  100-1000
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ng/ml. Calibration graphs were plotted using peak areas of standard drugs vs. concentration of
standard solutions, fig. 7.2.21-7.2.30. The slope, intercept and correlation coefficient values
were found to be 41.64, 6219.9 and 0.997 respectively, for Acebrophylline and 29.821,8562
and 0.998 respectively, for Montelukast.
Precision 
Precision of method was demonstrated by 
• Intraday precision 
• Inter day precision 
a. Intraday precision 
Intraday precision was found out by carrying out analysis of standard drug solutions at
two different concentrations in the linearity range for three times on the same day and % RSD
was calculated 
Table: 7.2.1. Intraday Precision
Level
Concentration
(ng/ml)
Peak Area %RSD
ABR MONTE ABR MONTE ABR MONTE
1 900 900
43087 35464
1.31 1.6944225 36062
43715 36685
2
400 400
23276 20636
1.66 1.5924058 20825
23625 21281
* RSD of three Observations 
ABR- Acebrophylline, MONTE- Montelukast
b. Inter day precision 
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Inter day precision was found out by carrying out analysis of standard drug solutions at
two different concentrations in the linearity range for three days over a period of one week and
% RSD was calculated.   
Table: 7.2.2. Inter day precision
Level
Concentration
(ng/ml)
Peak Area %RSD
ABR MONTE ABR MONTE ABR MONTE
1
900 900
43087 35464
1.19 1.062 43562 35986
3 44125 36212
1
400 400
23276 20436
1.48 1.992 23598 20789
3 23975 21265
* RSD of three Observations 
ABR- Acebrophylline, MONTE- Montelukast
Accuracy 
To study the reliability, suitability and accuracy of the method, recovery studies were
carried out  by standard addition method.  To an equivalent  quantity of  formulation powder
(10mg), 9.5mg of standard Montelukast sodium was added to it (standard addition method), so
that sample contains 10mg each of Acebrophylline and Montelukast sodium. Then a known
quantity of  standard  Acebrophylline and Montelukast  were added  to  50% and 100% level
extracted with mobile phase and made upto mark with same. This solution was further diluted.
The concentration of drugs present in resulting solution was determined using assay method
and percentage recovery and % RSD were calculated
Table:7.2.3.Recovery Studies
Drug Amount added Amount % Recovery % RSD*
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(mg) (%) recovered (mg)
MONTE 6(100%) 5.99 99.8
1.32
3(50%) 3.00 100 1.26
ABR 6 (100%) 6.1 102
1.05
3 (50%) 3.14 104 1.03
* RSD of three Observations 
MONTE = Montelukast ,ABR = Acebrophylline
Robustness 
1. In  order  to  demonstrate  the  robustness  of  the  method,  the  following  optimized
conditions were slightly varied.
2. λ 2% in ratio of Acetonitrile in mobile phase, fig. 7.2.17-7.2.18.
3. ± 0.2 units in pH of buffer, fig. 7.2.19-7.2.20.
The response factors for these changed chromatographic parameters were almost same
as that of the fixed  chromatographic  parameters and hence developed method is said to be
robust. The values are shown in table 7.2.7
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Fig: 7.2.16. Calibration graph of Acebrophylline by RP-HPLC.
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Fig: 7.2.17. Calibration Graph of Montelukast by RP-HPLC   
Table: 7.2.4. Calibration data of Acebrophylline and Montelukast by RP-HPLC
S.No Concentration (ng/ml)
Peak Areas
Montelukast Acebrophylline
1 100 11573 9768
2 200 14880 13599
3 300 17168 19928
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4 400 20436 23276
5 500 23738 27153
6 600 25771 31851
7 700 29963 35013
8 800 32119 39902
9 900 35464 43087
10 1000 38527 47642
Table: 7.2.5. Robustness data of Acebrophylline and Montelukast by RP-HPLC
Factor Value
Peak Area %RSD
MONTE ABR MONTE ABR
pH
3.8
4
4.2
1264103
1256438
1238769
577442
589454
575789
1.0 1.2
Mobile
Phase
10 mMPhosphatebuffer pH
4 and Acetonitrile in the
ratio of (17:83, v/v)
1537653 625424
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10 mMPhosphatebuffer pH
4 and Acetonitrile in the
ratio of (15:85, v/v)
10 mMPhosphatebuffer pH
4 and Acetonitrile in the
ratio of (13:87, v/v)
1558786
1579945
629746
625087
1.3 0.4
Robustness (change in mobile phase ratio)
Fig: 7.2.18. 10 mM Phosphate buffer and Acetonitrile (17:83, v/v)
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Fig:
7.2.19. 10 mM Phosphate buffer and Acetonitrile (13:87, v/v)
Robustness (change in the pH of the buffer)
Fig: 7.2.20. 10 mM Phosphate buffer (pH 3.8): Acetonitrile (15:85)
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Fig: 7.2.21. 10 mM Phosphate buffer (pH 4.2): Acetonitrile (15:85)
7.2.7. ANALYSIS OF FORMULATION
Fixed Chromatographic conditions were applied for the analysis of formulation. 
Preparation of Standard Solution 
Stock  solutions  containing  concentrations  of  10µg/ml  of  Acebrophylline  and
Montelukast  were  prepared  using  mobile  phase.  This  solution  was  suitably  diluted  to  get
aliquots  of  standard  solutions  containing  100  to  1000ng/ml  of  Acebrophylline  and
Montelukast.
 Preparation of Sample Solution 
Twenty tablets (ABROFYL-M) are powdered and the average weight was calculated. A
quantity equivalent to 10 mg of drug was dissolved in mobile phase and to it known quantity of
standard  Montelukast  were  added.  Finally  the  volume  was  made  up  to  get  a  working
concentration of 600 ng/ml each ofAcebrophylline and Montelukast.
 Recording of Chromatograms 
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A steady baseline was recorded with the fixed chromatographic conditions. Standard
drug solutions containing 100 to 1000ng/ml of Acebrophylline and Montelukast were injected
and chromatograms were recorded, fig. 7.2.21-7.2.30.
Retention  times  of  Acebrophylline  and  Montelukast  were  found  to  be  3.6  and
6.7minutes. This was followed by injection of sample solution obtained from the formulation,
fig. 7.2.31
Calibration curves were plotted using peak areas of standard drugs vs concentration of
corresponding standard solutions. Peak areas of the sample chromatograms were compared and
amount of Acebrophylline and Montelukast were calculated and tabulated.
Table: 7.2.6.Analysis of Formulation
Drug Label claim
(mg)
Amount found
(mg)
%Label
claim %RSD*
Montelukast 10 10.2 102 1.37
10.4 104
Acebrophylline 200 199.6 99.8 0.14
200 100
* RSD of three observations.
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7.2.9. SYSTEM SUITABILITY TESTING
 System suitability  test  parameters  like  Resolution,  Retention  Time,  Theoretical  plate  and
Tailing factor are shown in Table 7.2.7.
Table: 7.2.7. System suitability parameters
Parameter Montelukast Acebrophylline
Retention time (min)
6.6 3.7
Theoretical plate 4246 2568
Tailing factor 1.05 1.26
Resolution ( min) 2.9
CHROMATOGRAMS OF STANDARD SOLUTIONS
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Fig:
7.2.22. 100 ng/ml of Montelukast and of Acebrophylline
Fig: 
7.2.23. 200ng/ml of Montelukast and Acebrophylline
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 Fig: 
7.2.24. 300 ng/ml of Montelukast and Acebrophylline
        
Fig: 7.2.25. 400ng/ml of Montelukast and Acebrophylline
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Fig: 
7.2.26. 500ng/ml of Montelukast and Acebrophylline
 Fig: 7.2.27. 600ng/ml of Montelukast and Acebrophylline
 Fig: 
7.2.28. 700 ng/ml of Montelukast and Acebrophylline
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  Fig:
7.2.29. 800 ng/ml of Montelukast and Acebrophylline
Fig: 
7.2.30. 900 ng/ml of Montelukast and Acebrophylline
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Fig: 7.2.31. 1000ng/ml of Montelukast and Acebrophylline
Analysis of formulation
Fig: 7.2.32. 600ng/ml of Montelukast and Acebrophylline
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8.RESULTS AND DISCUSSION
8.1. UV SPECTOSCOPIC METHOD
8.1.1. Simultaneous equation method
Estimation  of  Acebrophylline  and  Montelukast  sodium  was  achieved  by
simultaneous equation method using 1800 double beam UV-Visible spectrophotometer.
The  linearity was  checked in  different  concentrations  and  Beers  law obeyed  in  the
concentration range of 6 to 24µg/ml for both Acebrophylline and Montelukast sodium.
The  slope,  intercept  and  correlation  coefficient  values  of  Acebrophylline  and
Montelukast sodium at  250nm are  0.023, 0.045, 0.998  and  0.032, 0.007, 0.997. The
slope, intercept and correlation coefficient values of Acebrophylline and Montelukast
sodiumat 273nm are 0.017, 0.038, 0.997 and0.040, 0.018 and 0.997.
The recovery studies were carried out to ensure the reproducibility and reliability
of the method by adding known amount of standard drugs and analysis was carried out
as per formulation procedure.
8.2. HPLC METHOD
In this method, optimization of different chromatographic parameters 
like selection of 
 Chromatographic method for separation
 Detection wavelength
 Different ionic strengths of mobile phase
 Mobile phase ratio
 Mobile phase pH
 Flow rate etc., were done.
A binary mixture of phosphate buffer and Acetonitrile was selected as the initial
mobile phase system for the determination of both drugs. A wavelength of 250nm was
selected  for  present  study.  Firstly,  various  concentrations  of  Phosphate  buffer  were
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tried.  From this,  10mM phosphate buffer was found to be ideal  for the work. Then
different pH’s of buffer were tired, out of which Phosphate buffer adjusted to pH 4 with
Orthophosphoric acid gave good peaks.  Then the ratio of mobile phase was determined
by varying the proportion of Phosphate buffer and Acetonitrile. Finally, the mixture of
10mM  phosphate  bufferbuffer  adjusted  to  pH  4  with  Orthophosphoric  acid  and
Acetonitrile (15:85% v/v) was employed for the simultaneous determination of both
drugs.  The retention times of Acebrophylline and Montelukast sodium were found to
be 3.7 and 6.6minutes respectively.  
The developed method was validated as per ICH guidelines.  Calibration graphs
were potted using standard peak areas vs. concentration of standard solutions.   The
slope, intercept and correlation coefficient values were found to be 29.821, 8562.5 and
0.998  for  Montelukast  sodium  and  41.64,  6219.9,  0.997  for  Acebrophylline
respectively.  Acebrophylline and Montelukast sodium were found to be linear in the
range of 100 to 1000ng/ml.  The LOD of Acebrophylline and Montelukast sodium were
found to be 0.087µg/ml and 0.010µg/ml respectively.  The LOQ of Acebrophylline and
Montelukast  sodium  were  found  to  be  0.289µg/ml  and  0.033µg/ml  respectively.
Precision of the developed method was studied under intraday precision and interday
precision of the injection.  Low % RSD values indicate that the method is precise.  The
developed  method  was  found  to  be  robust.   The  validated  liquid  chromatographic
method was applied to simultaneous determination of Acebrophylline and Montelukast.
9. SUMMARY AND CONCLUSION
SUMMARY
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• Optimization  of  the  mobile  phase  was  performed  based  on  resolution,
asymmetric  factor  and  peak  area  obtained  for  both  Acebrophylline  and
Montelukast sodium.
•  The mobile phase combination of 10mM Phosphate buffer: acetonitrile 15:85PH
4.00 (adjusted with Orthophosphoric acid) found to be satisfactory and gave two
symmetric and well resolved peaks for Acebrophylline and Montelukast sodium.
•  The retention time for Acebrophylline and Montelukast sodium were 3.7 and
6.6, respectively. 
• The method gives good resolution between both the compounds with a short
analysis time
• The method was validated as per ICH Guidelines.
• The calibration curve for Acebrophylline was obtained by plotting the peak area
of Acebrophylline versus the concentrations of Acebrophylline and Montelukast
over the range of 100-1000ng/ml , and it was found to be linear with r2 = 1. The
recoveries of Acebrophylline and Montelukast sodium were found to be in the
range of 98%-100% and 100%-104% within precision RSD of 1.32 and 1.05 for
Acebrophylline and Montelukast sodium. 
• The system suitability parameters such as theoretical  plates and tailing factor
were found to be 2568, 1.26 and 4246, 1.05 respectively for Acebrophylline and
Montelukast sodium.
•  The  Limit  of  Detection  (LOD)  and  Limit  of  Quantification  (LOQ)  of  the
developed  method  were  determined  by  injecting  progressively  low
concentrations of the standard solutions using the developed RP-HPLC
 method. 
• The LOD is the smallest concentration of the analyte that gives a measurable
response (signal to noise ratio of 3). The detection limit (LOD) was found to be
0.08µg/ml  for  Acebrophylline  and  0.01µg/ml  for  Montelukast  sodium
respectively.
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• The LOQ is the smallest concentration of the analyte, which gives response that
can be accurately quantified (signal to noise ratio of 10). 
• The quantitation limit (LOQ) was found to be 0.289µg/ml for Acebrophylline
and 0.033µg/ml for Montelukast sodium respectively. 
• The method was found to be simple, sensitive, accurate and precise.
• Proposed  study  describes  a  new  RP-HPLC  method  for  estimation  of
Acebrophylline and Montelukast sodium combination in mixture using simple
mobile phase. 
• Therefore,  the  proposed  method  can  be  used  for  routine  analysis  of
Acebrophylline and Montelukast sodium their combined dosage form. 
CONCLUSION 
In the current  study a new RP-HPLC method for estimation of Acebrophylline  and
Montelukast sodium combination in mixture using simple mobile phase was developed,
optimized  and  validated.  The  developed  method  is  simple,  sensitive,  accurate  and
precise. The developed method can be used for routine analysis of Acebrophylline and
Montelukast sodium in a combined dosage form.
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